<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="147">
  <!-- This xml conforms to:  http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>Information obtained from ClinicalTrials.gov on October 20, 2011</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01213940</url>
  </required_header>
  <id_info>
    <org_study_id>10-131</org_study_id>
    <nct_id>NCT01213940</nct_id>
  </id_info>
  <brief_title>Vascular Endothelium Changes After Bariatric Surgery (Endothelial Progenitor Cells)</brief_title>
  <acronym>EPC</acronym>
  <official_title>Vascular Endothelium Changes After Bariatric Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of South Alabama</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>American Society for Metabolic and Bariatric Surgery</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of South Alabama</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Improvement in cardiovascular mortality is related to changes in pathologic autoantibodies
      and in the number of circulating functional replicative competent endothelial progenitor
      cells (EPC's) after bariatric surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Same as above
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2010</start_date>
  <completion_date type="Anticipated">September 2012</completion_date>
  <primary_completion_date type="Anticipated">September 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation:  Non-Randomized, Intervention Model:  Parallel Assignment, Masking:  Open Label</study_design>
  <primary_outcome>
    <measure>Change in plasma autoantibody levels</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Primary outcome is the change in plasma autoantibody levels (endothelial barrier function) 6 months after enrollment to surgery (LRYGB) or to standard medical therapy (SMT).</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Diabetes Mellitus, Non-Insulin-Dependent</condition>
  <arm_group>
    <arm_group_label>baratric surgery</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>surgery vs.weight loss program 6 months prior to bariatric surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>pre-bariatric weight loss program</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>weight loss program prior to bariatric surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>pre-bariatric weight loss program</intervention_name>
    <description>standard 6 month physician directed pre-bariatric weight loss program</description>
    <arm_group_label>pre-bariatric weight loss program</arm_group_label>
    <other_name>weight loss program</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>bariatric surgery</intervention_name>
    <description>bariatric surgery for weight loss</description>
    <arm_group_label>baratric surgery</arm_group_label>
    <other_name>bariatric surgery</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 2 Diabetes, Glucose &gt; 200mg/dl, currently be ing treated with oral medications
             and HGA1c . 6.5, and BMI .35.

        Exclusion Criteria:

          -  Type 1 Diabetes
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William O Richards, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of South Alabama, Department of Surgery</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of South Alabama</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36617</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>William O Richards, MD</last_name>
      <phone>251-471-7993</phone>
      <email>brichards@usouthal.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2011</verification_date>
  <lastchanged_date>March 22, 2011</lastchanged_date>
  <firstreceived_date>September 30, 2010</firstreceived_date>
  <responsible_party>
    <name_title>William O. Richards, MD</name_title>
    <organization>University of South Alabama, Department of Surgery</organization>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
</clinical_study>
